**Core tip:** ATG5-ATG12 protein expression was increased in hepatitis B virus (HBV)-transfected HepG2.2.15 cells when they were compared with HepG2 cells and was increased in tumor liver tissues compared to adjacent non-tumor tissues from hepatocellular carcinoma (HCC) patients with HBV infection. We showed that silencing of ATG12 increased cell apoptosis of HepG2.2.15 cells but not HepG2 cells under starvation conditions. These results suggest that ATG5-ATG12 proteins are important for the survival of HBV-associated HCC during states of limited tumor nutrients. The inhibition of ATG12 might be a good target for HBV-associated HCC treatment.

INTRODUCTION
============

Previous studies have reported that HBV expression is correlated with autophagy induction\[[@B1]-[@B3]\]. HBV enhances and uses autophagy for its replication *via* the HBx protein, which binds and activates phosphatidylinositol-3-kinase class 3 (PIK3C3), an enzyme important for the initiation of autophagy. Autophagy inhibitors or the silencing of enzymes essential for the formation of autophagosomes suppresses HBV DNA synthesis with a minimal effect on the HBV mRNA levels\[[@B2]\]. The role of autophagy in the production of HBV virions was demonstrated in HBV transgenic mice with a liver-specific deficiency of Atg5\[[@B4]\]. We recently confirmed that ATG12 knock down reduced HBV DNA levels in HepG2.2.15 cells and induced the interferon signaling pathway, suggesting that autophagy machinery may aid HBV survival by reducing antiviral innate immunity\[[@B5]\].

Many studies have provided evidence to support the role of autophagy in human cancer. Beclin-1 was the first mammalian autophagy gene to be identified. The monoallelic deletion of Beclin-1 at chromosome 17q21 is sporadically observed in approximately 75% of ovarian cancers\[[@B6],[@B7]\], 50% of breast cancers\[[@B8]\], and 40% of prostate cancers\[[@B9]\]. Other mutations in autophagy genes such as Atg5, Atg12, Atg9B are frequent in gastric and colon cancers\[[@B10]\]. UVRAG, a Beclin1-interacting protein\[[@B10],[@B11]\] and Atg4C were also shown to suppress tumor gene activity\[[@B12]\]. Liver-specific Beclin-1 knockout heterozygous mice showed increased rates of hepatocellular carcinoma in old aged mice\[[@B13],[@B14]\]. Furthermore, mosaic Atg5^-/-^ mice developed benign liver tumors at 6-mo of age\[[@B15]\] and Atg7 hepatocyte-specific knockout mice also developed liver tumors later in life\[[@B15]\]. These data support the idea that autophagy defects contribute to tumorigenesis.

However, autophagy deficient cells can occur *via* cellular damage caused by dysfunctional mitochondria, oxidative stress, endoplasmic reticulum stress, necrosis and p62 accumulation\[[@B16]\]. The accumulation of cell damage can lead to chromosome instability\[[@B17]\] and inflammatory responses\[[@B18]\], resulting in tumor development. Although, autophagy functions as a tumor suppressor in primary cells, it is important for cancer cell survival. Interestingly, spontaneously occurring liver tumors did not progress in chimeric mice with Atg5 or Atg7 loss\[[@B15]\]. This finding implies that autophagy is required for tumor progression. Additionally, autophagy is required for cancer progression of other types of cancers. For example, an Atg3 deletion in hematopoietic cells prevents BCR-Abl-mediated leukemia\[[@B19]\]. Some tumor cells are susceptible to growth inhibition or death when autophagy is inhibited. Guo et al\[[@B20]\], found that Ras-driven tumors required autophagy for tumor cell survival upon starvation. Therefore, autophagy has a dual-function in cancer. It functions as a tumor suppressor during cancer initiation, but also functions to promote tumor progression and metastasis later in the development process.

Because HBV infection is associated with hepatocellular carcinoma (HCC) and requires the induction of autophagy for its survival, we investigated the involvement of autophagic genes in cancer cell survival using HBV-associated HCC and non HBV-HCC cell lines and liver tissues.

MATERIALS AND METHODS
=====================

Cell lines
----------

The immortalized human liver epithelial cell line (THLE-2; ATCC^®^ CRL-2706™, Manassas, VA, United States) was cultured in BEGM medium (CC3170 Bullet Kit; Lonza, Walkersville, MD, United States) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 5 ng/mL epidermal growth factor and 70 ng/mL phosphoethanolamine and maintained at 37 °C in 5% CO~2~. The flasks were precoated with a mixture of 0.01 mg/mL fibronectin, 0.03 mg/mL bovine collagen type I and 0.01 mg/mL bovine serum albumin dissolved in BEBM medium. The human hepatocellular carcinoma (HepG2) and HBV-transfected HepG2.2.15 cell lines were obtained from Professor Antonio Bertoletti (Singapore Institute for Clinical Sciences, A\*Star). These two cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco, United States) supplemented with 10% heat-inactivated FBS, 100 U/mL penicillin, and streptomycin at 37 °C in 5% CO~2~. For HepG2.2.15 cells, the medium was supplemented with 150 μg/mL of G418 (Geneticin; Gibco, United States) to maintain HBV plasmids.

Autophagy induction
-------------------

To induce starvation conditions, the cells were incubated in serum-free Earle's balanced salt solution (EBSS; starvation medium; Invitrogen, United States) for the indicated number of hours (between 4-8 h).

Human HCC samples
-----------------

Human liver tissues were obtained from King Chulalongkorn Memorial Hospital. The use of tissue biopsy was approved by the Institutional Review Board (IRB No. 396/55), Faculty of Medicine, Chulalongkorn University. The sections of tumor tissue and adjacent non-tumor tissue were performed at the Department of Pathology, Chulalongkorn University. The tissue samples were divided into two groups: HBV-infected and non-HBV infected groups. The diagnosis of HBV infection from HCC patients was established by seropositivity for HBsAg, HBV viral DNA, anti-HBcAg and seronegativity to anti-HBsAg. All fresh tissue samples were snap frozen in liquid nitrogen and stored at -80 °C prior to use.

RNA extraction and cDNA synthesis
---------------------------------

Total cellular RNA was extracted using Real Genomics Total RNA Extraction kit (RBC Bioscience, Taiwan). The quantity of RNA was measured using a spectrophotometer. RNA concentrations in a solution were read and a 260 nm absorbance reading of 1.0 was equivalent to about 40 μg/mL of RNA and the ratio of absorbance at 260 and 280 nm was used to assess the RNA purity of RNA preparations. Then 1 μg of total RNA was converted to cDNA using High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems, United States).

Analysis of mRNA expression using real-time quantitative PCR
------------------------------------------------------------

PCR reactions were performed in a 20 μL reaction volume in a 96-well plate (Applied Biosystems, United States). The PCR mixture contained 2 μL of cDNA template, 10 μL of commercial (2 ×) Power SYBR^®^ Green PCR Master Mix (Applied Biosystems), and each primer at a final concentration of 0.5 μmol/L. Real-time PCR runs were carried out using an ABI Thermal cycler 7500 real-time PCR instrument (Applied Biosystems). The conditions for thermal cycling were as follows: initial denaturation at 95 °C for 10 min, followed by 40 amplification cycles at 95 °C for 15 s and then 60 °C for 1 min. For each PCR run, a negative (no-template) control was used to test for false-positive results or contamination. The absence of nonspecific amplification was confirmed by generating a melt curve using the Applied Biosystems real-time PCR system software. The primers utilized in this study are summarized in Table [1](#T1){ref-type="table"}.

###### 

Sequences of primers used in this study

  **Gene names**   **Primer sequences (5'-3')**   
  ---------------- ------------------------------ -------------------------
  *Beclin-1*       BECN1-F                        GGATCAGGAGGAAGC
                   BECN1-R                        GATGTGGAAGGTTGC
  *ATG5*           ATG5-F                         GCTTCGAGATGTGTGGTTTGG
                   ATG5-R                         ACTTTGTCAGTTACCAACGTCA
  *ATG12*          ATG12-F                        TTGTGGCCTCAGAACAGTTG
                   ATG12-R                        GAGAGTTCCAACTTCTTGGTCTG
  *ATG9A*          ATG9A-F                        CGTGTGGGAAGGACAG
                   ATG9A-R                        GGCGCTTTCTCCACTC
  *ATG4B*          ATG4B-F                        TCCATAGGCCAGTGGTACG
                   ATG4B-R                        TGCACAACCTTCTGATTTCC
  *B-actin*        B-actin-F                      ACCAACTGGGACGACATGGAGAA
                   B-actin-R                      GTGGTGGTGAAGCTGTAGCC

Quantifying relative gene expression
------------------------------------

To analyze the relative gene expression data, we used real-time quantitative PCR and the 2^-ΔΔ^*^CT^* method\[[@B21]\]. The C~T~ values were obtained from real-time PCR instrumentation. The quantity of mRNA relative to a reference gene was calculated using the formula 2^-Δ^*^CT^*, where Δ*CT* = (C~T\ target\ RNA~ - C~T\ reference\ RNA~). Comparison of gene expression was based on a comparative C~T~ method (ΔΔ*CT*), and the relative RNA expression was quantified according to the formula of 2^-ΔΔ^*^CT^*, where ΔΔ*CT* = (C~T\ target\ RNA\ (experimental\ group)~ - C~T\ reference\ RNA\ (experimental\ group)~) - (C~T\ target\ RNA\ (control\ group)~ - C~T\ reference\ RNA\ (control\ group)~). Genes with high expression levels were selected for the functional study.

Western blot analysis
---------------------

All cell lines and human liver tissues samples were lysed with RIPA buffer (25 mmol/L Tris-HCl, pH 7.6, 150 mmol/L NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate). After sonication, protein concentrations of cell lysates were measured using BCA assay (Thermo Scientific, United States). Then 20 μg of protein from each cell line was loaded onto a 12% polyacrylamide gel and run at 130 V for 80 min. The proteins were transferred onto nitrocellulose membranes and were immunoblotted with primary mAb against Atg9a, Atg12, cNotch1, GAPDH (dilution, 1:1000; rabbit mAb; Cell Signaling Technologies, United States) and Atg4b (dilution, 1:1000; mouse mAb; Abcam, United States). After washing, the membranes were incubated with secondary antibodies conjugated with horseradish peroxidase (dilution 1:2000) and were analyzed with enhanced chemiluminescence (ECL) substrate (SuperSignal West Femto Chemiluminescent Substrate; Thermo Scientific). Images were quantified using a Licor-odyssey image system (LI-COR^®^, United States).

Determination of HBx gene effect on autophagic gene expression
--------------------------------------------------------------

HepG2 cells were grown in DMEM supplemented with 10% FBS, antibiotic-free at 37 °C in 5% CO~2~ for 24 h. HepG2 cells were transfected with 500-1000 ng of pGFP-HBx plasmids (Addgene, MA, United States) or pGFP (negative control) using 1-3 μL of Lipofectamine^®^ 2000 Transfection Reagent (Invitrogen, United States). Opti-MEM^®^I Reduced Serum Medium (Invitrogen) was used to dilute Lipofectamine^®^ 2000 and plasmids, which were then gently mixed at a 1:1 ratio, incubated for 40 min at room temperature. HepG2 cells were diluted in complete growth medium without antibiotics to a final concentration of 4 × 10^5^ cells/mL, then the cells were added to culture plates with plasmid-Lipofectamine^®^ 2000 complexes and gently mixed by rocking the plate. The cells were incubated for 24-72 h at 37 °C in a 5% CO~2~ incubator. The relative autophagic gene expression was detected by real-time quantitative PCR.

RNA interference
----------------

HepG2 and HepG2.2.15 cells were transiently transfected with 500 ng of short hairpin RNA (shRNA) plasmid specific to ATG12 or a negative control (SureSilencing shRNA Plasmid; Qiagen, United States). The shATG12 plasmids contained following sequence: 5'-GCAAATCCTCTATGCCTTCTT-3'. Negative controls were inserted with a mock target sequence as follows: 5'-GGAATCTCATTCGATGCATAC-3'. Transfection of shRNA plasmids was carried out using Lipofectamine^®^ 2000 (Invitrogen) according to the manufacturer's instructions. At 72 h post-transfection, cells were collected and the silencing efficiency of the shRNA was detected by western blotting.

Flow cytometric analysis
------------------------

Specific autophagic silenced cells (shATG12) were assayed for apoptosis using PE-labeled annexin V staining (BioLegend, San Diego, CA, United States) and Fixable Viability Dye eFluor^®^ 780 staining (eBioscience, CA, United States). Total apoptotic cells and early apoptotic cells were defined as annexin V-positive and Fixable Viability Dye eFluor^®^ 780-negative and late apoptotic cells were defined as annexin V-positive and Fixable Viability Dye eFluor^®^ 780-positive. For cell cycle analysis, cells were fixed with 70% ice-cold ethanol for at least 2 h on ice. The supernatant was removed, and the pellet was washed and treated with RNaseA to resuspend cells. Cells were then stained with propidium iodide (PI) solution at room temperature in the dark for 30 min. Cells were acquired on a FACScan (BD Biosciences, United States) and analyzed with FlowJo 10.0 software (FlowJo LLC., United States).

Statistical analysis
--------------------

Significant differences were determined by unpaired *t* test with GraphPad Prism software, version 5.0 (San Diego, CA, United States). Statistical significance was set at a *P* value of \< 0.05.

RESULTS
=======

Expression profile of autophagic genes in cell lines and HCC biopsy tissue
--------------------------------------------------------------------------

To investigate the involvement of autophagy in HCC, we used Beclin-1 as a marker for HBV-induced autophagy under starvation conditions. We analyzed Beclin-1 mRNA expression in HBV-transfected HepG2.2.15 cells and the parental cell line, HepG2. At 4 h post-starvation, Beclin-1 was up regulated in both cell lines and was then down regulated at 8 h (data not shown). Thus, we selected autophagy induction with starvation in EBSS for 4 h for all subsequent experiments.

Autophagy related genes that represent each major part of the autophagy machinery including (1) induction step (Beclin1); (2) the first ubiquitin-like conjugation molecules (ATG5 and ATG12); (3) the cysteine protease that catalyzes the second ubiquitin-like conjugation molecules (ATG4B); and (4) the transporter membrane required for autophagosome formation (ATG9A) were tested. The mRNA expression levels of these selected molecules were determined at baseline and at 4 h post-culture in EBSS. There were no significant differences at baseline (data not shown). At 4 h post starvation, Beclin1 mRNA was down regulated in HepG2.2.15 compared to THLE2 and HepG2 (*P =* 0.0213 and *P =* 0.0236, respectively) (Figure [1A](#F1){ref-type="fig"}). No significant difference was observed for ATG4B expression between HBV-transfected HepG2.2.15 and HepG2, but it was significantly increased in HepG2 and HepG2.2.15 compared with THLE-2 (*P =* 0.0002 and *P =* 0.0007, respectively) (Figure [1E](#F1){ref-type="fig"}). ATG9A mRNA expression was higher in HepG2 and HepG2.2.15 compared to THLE2 but significantly down regulated in HBV-transfected HepG2.2.15 compared with HepG2 (*P =* 0.0013) (Figure [1D](#F1){ref-type="fig"}). Only the mRNA expression of ATG5 and ATG12 was significantly increased in HBV-transfected HepG2.2.15 compared with HepG2 cells (*P =* 0.0027 (Figure [1B](#F1){ref-type="fig"}) and *P =* 0.0039 (Figure [1C](#F1){ref-type="fig"}), respectively). The results of mRNA levels were confirmed by western blot analysis. ATG5-ATG12 proteins were up regulated in HBV-transfected HepG2.2.15 whereas ATG9A were down regulated compared to HepG2 cells. There was no difference in ATG4B protein expression between HBV-transfected HepG2.2.15 and HepG2 (Figure [1F](#F1){ref-type="fig"}).

![Quantitative real-time reverse transcriptase-polymerase chain reaction analysis of Beclin-1 (A), ATG5 (B), ATG12 (C), ATG9A (D) and ATG4B (E) mRNA in THLE-2, HepG2 and HepG2.2.15 cell lines at 4 h post-culture in EBSS. β-actin was used as an internal control. Data represent the mean and SE from five independent experiments. Western blotting with specific antibodies was used to analyze ATG12, ATG9A and ATG4B protein expression in THLE-2, HepG2 and HepG2.2.15 cells at 4 h post-culture in EBSS (F). GAPDH was used as a protein loading control.](WJG-22-8361-g001){#F1}

Next, we analyzed ATG5-ATG12 levels in tumor tissues compared to adjacent non-tumor tissues from HCC patients with or without HBV infection. In HBV-associated HCC tissues, ATG5-ATG12 protein levels were increased in the majority of tumor liver tissues compared to adjacent non-tumor tissues (9/10 sample pairs) (Figure [2A](#F2){ref-type="fig"} and C). In non-HBV HCC, ATG5-ATG12 protein levels were only increased in 3/8 tumor liver tissue samples (Figure [2B](#F2){ref-type="fig"} and C). These results suggested that ATG5-ATG12 proteins might have a selective advantage in HBV-associated HCC compared to non-HBV HCC.

![Quantification of ATG5-ATG12 protein levels from hepatitis B virus-infected hepatocellular carcinoma patients and non-hepatitis B virus hepatocellular carcinoma patients. Western blotting with specific antibodies was used to analyze ATG12 protein expression in HBV-associated HCC and non-HBV HCC. GAPDH was used as a protein loading control. Graphs showing the intensity band ratio (tumor tissue/adjacent non-tumor tissue) quantified using the LI-COR^®^ image system from western blot analysis were shown in A and B. Representative western blot results were shown in C. HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma.](WJG-22-8361-g002){#F2}

Effect of HBx gene on autophagic gene expression
------------------------------------------------

The X protein was shown to induce HBV replication by increasing Beclin-1 transcription leading to the induction of autophagy\[[@B1]\]. In this study, we analyzed the effect of HBx on Beclin-1 and on ATG12 by transfection of HepG2 cells with the pGFP-HBx plasmid. Then, we analyzed Beclin-1 and ATG12 mRNA expressions using quantitative real-time RT-PCR. We found that Beclin-1 (*P =* 0.0027) (Figure [3A](#F3){ref-type="fig"}) and ATG12 (*P =* 0.0139) (Figure [3B](#F3){ref-type="fig"}) mRNA expression were significantly increased in HepG2-GFP-HBx compared with HepG2-GFP after 48 h of transfection. These results suggested that HBX plays a role in ATG12 induction, either directly or indirectly through Beclin1.

![Quantitative real-time reverse transcriptase-polymerase chain reaction analysis of *Beclin-1* (A) and *ATG12* (B) mRNA expression in HepG2-GFP and HepG2-HBx transfected cell lines. β-actin was used as an internal control. Data represent the mean and SE from three independent experiments.](WJG-22-8361-g003){#F3}

ATG12 gene silencing in HepG2 and HepG2.2.15
--------------------------------------------

Next, we studied the functional role of the ATG12 autophagic gene by monitoring the biological effect after knockdown of its expression. Cells containing plasmids with the greatest silencing efficiency were subjected to western blot analysis for protein expression. The transfection efficiency was estimated by monitoring GFP expression under inverted fluorescence microscope (data not shown). The protein level of ATG12 in transfected HepG2 and HepG2.2.15 cells was decreased compared with mock controls (Figure [4A](#F4){ref-type="fig"}).

![Apoptosis assays of HepG2 and HepG2.2.15 cells transfected with shATG12 or shNeg (control). A: Suppression of ATG12 expression was done by RNA interference. Western blotting was used to analyze ATG12 proteins from mock treatment (control) and ATG12 knockdown (shATG12) in HepG2 and HepG2.2.15 cells; B: GAPDH was used as a protein loading control. Cells were transiently transfected with shRNA plasmids for 72 h (normal) and then cultured in EBSS for 4 h (starvation). Bar graphs show the percentage of total apoptotic cells detected by Annexin V binding. Data represent the mean and SE from three independent experiments.](WJG-22-8361-g004){#F4}

Effect of ATG12 knock down on cell apoptosis and cell cycle progression
-----------------------------------------------------------------------

We investigated apoptosis and cell cycle progression in HepG2.2.15 cells compare to HepG2 cells after the silencing of ATG12. The percentage of apoptotic cells was slightly increased (8.3%) in ATG12-silenced HepG2 but unchanged in HepG2.2.15 under normal conditions, which is similar to what we have previously reported\[[@B5]\]. Under starvation conditions with EBSS, the percentage of apoptotic cells increased 11.4% in ATG12-silenced HepG2.2.15 but did not change in ATG12-silenced HepG2 (Figure [4B](#F4){ref-type="fig"}). No significant changes in cell cycle progression were observed in either cell line (Figure [5](#F5){ref-type="fig"}). These results suggest that ATG5-ATG12 proteins are important for the survival of HBV-associated HCC during states of limited tumor nutrients.

![Cell cycle analysis of HepG2 and HepG2.2.15 cells transfected with shATG12 or shNeg (control). A: Cells were transiently transfected with shRNA plasmids for 72 h (normal) and then cultured in EBSS for 4 h (starvation); B: Bar graphs show the percentage of cells in each phase. Data represent the mean and SE from three independent experiments.](WJG-22-8361-g005){#F5}

Analysis of combination treatment using ATG12-silencing and Notch inhibition
----------------------------------------------------------------------------

We recently reported that Notch signaling played a role in cell cycle progression and apoptosis, particularly in HBV-associated HCC\[[@B22]\]. Because ATG12 was up regulated in HepG2.2.15 compared to HepG2, and plays a role in cell apoptosis, we assessed the effect of ATG12 silencing in combination with a Notch inhibitor in the HepG2.2.15 cell line. Gamma-secretase inhibitors, also known as N-\[N-(3,5-difluorophenacetyl)-L-alanyl\]-S-phenylglycine t-butyl ester; DAPT, is used to block the Notch pathway\[[@B23]\]. When using DAPT combined with gene silencing of ATG12 under starvation conditions, HepG2 cell apoptosis was increased from 38.5% to 48.3%, compared to DAPT treatment alone, although there was no synergistic effect (Figure [6](#F6){ref-type="fig"}). Interestingly, the combination blockade of DAPT and ATG12 gave the opposite result by decreasing the apoptosis rate in HepG2.2.15 from 55.6% to 50.4% (Figure [6](#F6){ref-type="fig"}). No significant changes in cell cycle progression were observed for the combination treatment of ATG12 siRNA and DAPT (Figure [7](#F7){ref-type="fig"}). These results suggested that autophagy and Notch signaling are independent from each other in HBV-expressing cells compared to non-HBV HCC.

![Apoptosis assays of HepG2 and HepG2.2.15 cells transfected with shATG12 or shNeg (control) pretreated with DAPT. A: Cells were transiently transfected with shRNA plasmids for 24 h, and then pretreated with DAPT (50 μmol/L, 48 h) and cultured in EBSS for 4 h (starvation); B: Bar graphs show the percentage of total apoptotic cells detected by Annexin V binding. Data represent the mean and SE from three independent experiments.](WJG-22-8361-g006){#F6}

![Cell cycle analysis of HepG2 and HepG2.2.15 cells transfected with shATG12, ATG9A or shNeg (control) pretreated with DAPT. A: Cells were transfected with shRNA plasmids for 24 h, and then pretreated with DAPT (50 μmol/L, 48 h), and cultured in EBSS for 4 h (starvation); B: Bar graphs show the percentage of cells in each phase. Data represent the mean and SE from three independent experiments.](WJG-22-8361-g007){#F7}

Finally, we analyzed ATG12 expression after treatment with DAPT and detected cleaved Notch1 expression after silencing *ATG12* genes at baseline. ATG12 mRNA was decreased by DAPT treatment in HepG2.2.15 (Figure [8A](#F8){ref-type="fig"}). Moreover, cleaved Notch1 was diminished in ATG12-silenced HepG2.2.15 under normal conditions (Figure [8B](#F8){ref-type="fig"}).

![Quantitative real-time reverse transcriptase-polymerase chain reaction analysis of ATG12 mRNA in HepG2 and HepG2.2.15 cells with DAPT treatment for 48 h. A: Data represent the mean and SE from three independent experiments; B: Notch activation was detected by cleaved Notch1 protein expression in HepG2 and HepG2.2.15 cells after silencing ATG12 for 72 h. GAPDH was used as a protein loading control.](WJG-22-8361-g008){#F8}

DISCUSSION
==========

Autophagy has been reported to be associated with HBV and HCC\[[@B13],[@B15],[@B24]\]. However, the mechanism is still poorly understood. Moreover, recent evidence suggests that specific ATG genes might contribute differently to viral infection and cancer development\[[@B25]-[@B28]\]. Some ATG genes have autophagy independent functions\[[@B29]-[@B32]\]. In this study, we focused on the ATG5-ATG12 complex that was up regulated in HepG2.2.15 and were highly expressed in HBV-associated HCC compared to non-HBV cell lines and HCC.

HBX appears to play a role in ATG12 induction, probably indirectly through the stimulation of Beclin-1 and PIK3C3\[[@B1],[@B2]\]. We showed that silencing of ATG12, which represented the elimination of the ATG5-ATG12 complex, increased cell apoptosis under starvation conditions in HepG2.2.15 but not in HepG2. These results suggested that ATG5-ATG12 is important for the survival of HBV-associated HCC during states of limited tumor nutrients. A previous study by Mao et al\[[@B33]\] showed that HepG2.2.15 cells have a higher survival rate than HepG2 cells after culturing in a starvation medium for 48 h. Cell death was reduced through activation of the autophagy pathway. However, our study did not show any significant difference between the rate of cell death for HepG2 and HepG2.2.15 after starvation for 4 h. This might be explained by our shorter starvation time. The inhibition of autophagy-induced liver cancer cell apoptosis under starvation conditions was reported by Chang et al\[[@B34]\] They showed that HepG2 and HuH6 induced autophagy (Beclin-1, ATG5 and LC3B expression) for cell survival under starvation conditions with serum-free medium or chemotherapy. The inhibition of autophagy *via* the silencing of autophagic genes (Beclin-1 and ATG5) or 3-MA treatment induced HuH6 cell apoptosis under starvation conditions\[[@B34]\]. A study by Liu et al\[[@B35]\] demonstrated that starvation with serum-free medium for 48 h induced autophagy and apoptosis in 7702, HepG2, Hep3B and Huh7 cell lines; however, the inhibition of autophagy *via* Bafilomycin A1 was not affected in HepG2 apoptosis under starvation conditions similar to our result. These results imply that targeting the inhibition of autophagy might have different effects depending on the cell type and various metabolic stress conditions present.

Although ATG12 has been demonstrated to have pro-apoptotic activity through the ATG12-ATG3 conjugate\[[@B36]\], ATG12 also has anti-apoptotic activity. In mammalian HeLa cells, disruption of autophagy by silencing ATG12 promotes cells to die *via* apoptosis under starvation conditions\[[@B37]\]. ATG12 and other autophagic proteins (LC3 and ATG5) are associated with mitochondrial quality control of human umbilical vein endothelial cells. ATG12, ATG5 and LC3B were up-regulated after mitochondrial damage, leading to increased anti-apoptotic effects and increased life span in an *in vitro* aging model\[[@B38]\]. The combination of trastuzumab with silencing of ATG12 reduces cell viability and tumor growth in nude mice\[[@B39]\]. Therefore, we suggest that the inhibition of ATG12 might be a good target for the treatment of HBV-associated HCC.

Many cancer drug treatments increase tumor cell autophagy to protect cancer cells from apoptosis. Autophagy inhibitors in combination with chemotherapy are designed to induce apoptosis in human cancers. For example, autophagy inhibition was previously shown to enhance the growth inhibitory effects of sorafenib\[[@B40]\] as well as the combination of vorinostat with sorafenib in HCC cell lines\[[@B41]\]. In this study, we examined apoptosis cell death after the inhibition of ATG12 in combination with Notch signaling in HepG2 and HepG2.2.15 cell lines. The combination treatment increased cell apoptosis in HepG2 cells. However, when we blocked both Notch signaling and ATG12 under starvation conditions, cell apoptosis did not increase. There appears to be some interaction between ATG12 and Notch signaling, specifically in HepG2.2.12, because the Notch inhibitor DAPT caused the down-regulation of ATG12 mRNA but this was not observed in HepG2. In addition, the inhibition of ATG12 impaired Notch activation in HepG2.2.15 but increased Notch activation in HepG2.

This observation regarding the regulation between autophagy and notch signaling in HepG2.2.15 was unexpected. Both autophagy and Notch signaling are highly conserved signaling pathways in eukaryotic cells. The core Notch signaling pathway is through the binding of Notch ligand to Notch receptor which induces two proteolytic cleavages, metalloprotease and γ-secretase, to release the Notch intracellular domain, which translocates to the nucleus and binds to DNA to regulate the transcription of target genes\[[@B42]\]. The Notch pathway is associated with both tumor suppression and tumorigenesis in HCC\[[@B43],[@B44]\]. The connection of autophagy and Notch signaling was demonstrated in Drosophila where the ATG4 mutation enhanced the notched-wing phenotype resulting in defective Notch signaling\[[@B45]\]. In contrast, the overexpression of ATG1 enhanced the notched-wing phenotype\[[@B46]\], suggesting that some autophagic proteins have additional functions independent of autophagy that are related to the enhancement or suppression of Notch signaling.

Mammalian target of rapamycin (mTOR) is a positive regulator of Notch signaling\[[@B47]\] and a negative regulator of autophagy\[[@B48]\]. Previous reports have shown that silencing of Notch1 activated phosphorylated Akt and decreased mTOR to induce glioblastoma cell apoptosis\[[@B49]\]. The inhibition of Notch signaling induced autophagy *via* PTEN-PI3K/Akt/mTOR pathway to promote the adipogenic differentiation of BM-MSCs\[[@B50]\]. Other studies have demonstrated that autophagy regulates Notch signaling by reducing the impact of Notch1 on stem cell differentiation. The silencing of autophagy (ATG7 or ATG16L1) induced Notch1 and cleaved Notch1 in HEK cells\[[@B51]\].

The unexpected relationship between autophagy and Notch signaling in HepG2.2.15 was different from HepG2 and might be explained by the HBV genome. The HBV X protein activates the NF-κB pathway (p65 and p50) *via* Notch signaling through a specific ligand and receptor to promote cell survival\[[@B52]\]. After treatment with DAPT, NF-κB expression was decreased\[[@B53]\]. Thus, the activation of NF-κB can either stimulate or inhibit autophagy *via* the upregulation of Beclin-1 in T-cells\[[@B54]\], whereas prolonged NF-κB activation suppresses ATG5 and Beclin-1 expression in macrophages\[[@B55]\]. However, the connection between HBV and Notch related autophagy needs further study.

In conclusion, our previous study demonstrated the role of autophagy machinery in HBV replication. We found that ATG12-knockdown reduced HBV DNA levels in HepG2.2.15 and induced the interferon signaling pathway. Thus, the ATG12 machinery of autophagy may aid HBV survival by reducing antiviral innate immunity\[[@B5]\]. Moreover, this study demonstrated that autophagy is related to HBV-associated cell death responses. Atg12 silenced HepG2.2.15 showed increased apoptosis under starvation conditions. The function of Atg12 seems to be dominated in HBV-associated HCC. These results suggested that ATG5-ATG12 is important for the survival of HBV-associated HCC during states of limited tumor nutrients. However, as mentioned previously that autophagy has a dual-function in cancer. Despite its role as tumor promotion in the later phase, it can act as a tumor suppressor during cancer initiation. Therefore, the therapeutic intervention that target autophagy has to take this information into consideration too. Moreover, our result showed that the use of autophagy inhibition in combination with other anti-tumor therapies such as Notch inhibitor, might not be a good strategy. Further characterization of HBV and Notch related autophagy is needed.

COMMENTS
========

Background
----------

Hepatitis B virus (HBV) infection is associated with hepatocellular carcinoma (HCC) and has been proved to induce autophagy for its replication and survival. The involvement of some autophagic genes on cancer cell survival is still unknown. Therefore, we investigated the role of ATG genes in HBV-associated HCC and non HBV-HCC in this study.

Research frontiers
------------------

Autophagy is a catabolic process for cell survival under nutrient limitation or stress conditions. However, autophagy can act as either an oncogene or tumor suppressor gene. A recent report showed that HBV used the autophagic pathway for its own benefit; however the molecular mechanism is still unclear.

Innovations and breakthroughs
-----------------------------

ATG5-ATG12 protein was up regulated in HepG2.2.15 and expressed in a high percentage of HBV-associated HCC compared to non-HBV cell lines and HCC. The Atg12 silenced HepG2.2.15 cell line had increased apoptosis under starvation conditions. This is the first study to show a function of Atg12 in apoptosis in HBV-associated HCC.

Applications
------------

These findings raise the possibility of targeting the autophagic pathway for the treatment of HBV-associated HCC patients.

Peer-review
-----------

This paper reported that ATG5-ATG12 protein expression was increased in HBV-transfected HepG2.2.15 cells compared to HepG2 cells and was increased in tumor liver tissues compared to adjacent non-tumor tissues from HCC patients with HBV infection. The silencing of ATG12 increased cell apoptosis under starvation conditions in HepG2.2.15 cells but not in HepG2 cells. Their results suggest that ATG5-ATG12 is important for the survival of HBV-associated HCC in the state of tumor nutrient limitation. The inhibition of ATG12 might be a good target for HBV-associated HCC.
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